Research Vision for UK announced today

NIHR plays key role in ambitious cross-sector plan for the future of clinical research delivery in the UK

hand and test tube

The UK Life Sciences Vision launched today sets a 10-year strategy for the sector to solve some of the biggest healthcare problems of our generation, including cancer and dementia

NIHR BioResource has a key role to play in this ambitious plan, working with the devolved administrations, the NHS, regulators, medical research charities and the life sciences industry.

There are 7 critical healthcare missions that agencies will work together at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing, monitoring and treating disease early, using innovative clinical trials to develop breakthrough products and treatments quickly to help save lives, and accelerating the development and adoption of new drugs, diagnostics, medical technology and digital tools.

The missions are:

  • Accelerating the pace of studies into novel dementia treatment
  • Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines
  • Sustaining the UK’s position in vaccine discovery, development and manufacturing
  • Treatment and prevention of cardiovascular diseases and its major risk factors, including obesity
  • Reducing mortality and morbidity from respiratory disease in the UK and globally
  • Addressing the underlying biology of ageing
  • Increasing the understanding of mental health conditions, including work to redefine diseases and develop tools to address them

The aim is to make the UK a leading global centre for innovative research design and delivery, across all types and phases of trials:

The NIHR, MHRA and NICE and the NHS will work with universities and research sponsors to ensure studies are delivered in the most innovative and effective ways that support rapid integration into routine care pathways.

The remarkable response of the UK’s world class life sciences sector to COVID-19 will be used as a blueprint to accelerate the delivery of life-changing innovations to patients, as part of the government’s new UK Life Sciences Vision published 7 July. 

The new UK Life Sciences Vision, co-developed with businesses and experts in the field, sets out a mission-led approach with bold ambition for the next decade to ensure scientific excellence, partnered with the dynamism of industry, is replicated to assist the NHS in solving the most pressing health challenges of our generation now and in the future.

Prime Minister Boris Johnson said:

“We are indebted to the ingenuity of UK life sciences and its pioneers, with the discovery of the Oxford-AstraZeneca vaccine and the seamless collaboration between our scientists, industry, regulators and NHS saving millions of lives during the pandemic.

We must make sure this is the norm and use this new way of working to search for life-changing breakthroughs against diseases such as cancer, dementia and obesity, as we have done with COVID.

That’s why we are setting out our new Life Sciences Vision to bottle the formula we have developed to tackle COVID and improve health outcomes for patients across the board in the UK, and secure jobs and investment in the process as we build back better.”

To read more about it please click on the following links: